Last reviewed · How we verify

biphasic human insulin 30

Novo Nordisk A/S · FDA-approved active Small molecule

biphasic human insulin 30 is a Insulin (premixed biphasic formulation) Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.

Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic namebiphasic human insulin 30
SponsorNovo Nordisk A/S
Drug classInsulin (premixed biphasic formulation)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

This formulation contains 30% soluble (rapid-acting) human insulin and 70% isophane (intermediate-acting) human insulin, allowing for a single injection that provides both immediate postprandial glucose control and basal insulin coverage. The rapid-acting component addresses mealtime glucose spikes, while the intermediate-acting component provides sustained glucose control between meals and overnight.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about biphasic human insulin 30

What is biphasic human insulin 30?

biphasic human insulin 30 is a Insulin (premixed biphasic formulation) drug developed by Novo Nordisk A/S, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does biphasic human insulin 30 work?

Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.

What is biphasic human insulin 30 used for?

biphasic human insulin 30 is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes biphasic human insulin 30?

biphasic human insulin 30 is developed and marketed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).

What drug class is biphasic human insulin 30 in?

biphasic human insulin 30 belongs to the Insulin (premixed biphasic formulation) class. See all Insulin (premixed biphasic formulation) drugs at /class/insulin-premixed-biphasic-formulation.

What development phase is biphasic human insulin 30 in?

biphasic human insulin 30 is FDA-approved (marketed).

What are the side effects of biphasic human insulin 30?

Common side effects of biphasic human insulin 30 include Hypoglycemia, Weight gain, Injection site reactions, Lipodystrophy.

What does biphasic human insulin 30 target?

biphasic human insulin 30 targets Insulin receptor and is a Insulin (premixed biphasic formulation).

Related